Business Description
Ascendis Pharma AS
NAICS : 325412
SIC : 2834
ISIN : DK0060615755
Total Employee Number:
1,189Compare
Compare
Traded in other countries / regions
ASND.USAASND1N.MexicoA1SN34.BrazilA710.Germany IPO Date
2026-04-21Description
Ascendis Pharma A/S is a Danish biopharmaceutical company that develops long-acting prodrug therapies using its TransCon technology platform, which is designed to release active drug in a controlled, predictable manner. Its commercial products include Skytrofa (lonapegsomatropin) for pediatric growth hormone deficiency and Yorvipath (palopegteriparatide) for hypoparathyroidism. The pipeline also includes TransCon CNP for achondroplasia and earlier-stage programs in endocrinology and oncology. The company sells primarily in the United States and Europe, with the United States accounting for most revenue, and it also maintains operations in other international markets. Revenue comes from product sales of its commercial therapies, alongside collaboration and licensing arrangements with partners. Ascendis Pharma is headquartered in Copenhagen, Denmark, and is listed on the Nasdaq Global Select Market.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.81 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.31 | |||||
Debt-to-EBITDA | 1.9 | |||||
Interest Coverage | 2.15 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 10.74 | |||||
Beneish M-Score | 2.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 143.2 | |||||
3-Year EBITDA Growth Rate | 39.6 | |||||
3-Year EPS without NRI Growth Rate | 31.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 51.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.99 | |||||
Quick Ratio | 2.32 | |||||
Cash Ratio | 1.75 | |||||
Days Inventory | 1225.15 | |||||
Days Sales Outstanding | 53.74 | |||||
Days Payable | 356.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | 0.79 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 91.29 | |||||
Operating Margin % | 24.92 | |||||
Net Margin % | 70.29 | |||||
EBITDA Margin % | 22.41 | |||||
FCF Margin % | 31.47 | |||||
OCF Margin % | 32.8 | |||||
ROE % | 265.94 | |||||
ROA % | 47.06 | |||||
ROIC % | 20.21 | |||||
3-Year ROIIC % | 80.27 | |||||
ROC (Joel Greenblatt) % | 140.36 | |||||
ROCE % | 33.53 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 20.73 | |||||
Forward PE Ratio | 24.28 | |||||
PE Ratio without NRI | 19.09 | |||||
Price-to-Owner-Earnings | 161.47 | |||||
PEG Ratio | 0.86 | |||||
PS Ratio | 13.87 | |||||
PB Ratio | 10.46 | |||||
Price-to-Tangible-Book | 10.48 | |||||
Price-to-Free-Cash-Flow | 43.49 | |||||
Price-to-Operating-Cash-Flow | 43.49 | |||||
EV-to-EBIT | 60.79 | |||||
EV-to-Forward-EBIT | 18.63 | |||||
EV-to-EBITDA | 56.19 | |||||
EV-to-Revenue | 12.6 | |||||
EV-to-Forward-Revenue | 6.35 | |||||
EV-to-FCF | 41.86 | |||||
Price-to-Graham-Number | 2.98 | |||||
| Price-to-Net-Current-Asset-Value | 27.77 | |||||
Earnings Yield (Greenblatt) % | 1.65 | |||||
FCF Yield % | 2.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ascendis Pharma AS Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 21,852.581 | ||
| EPS (TTM) (MXN) | 228.148 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 4270 - 4424.97 | ||
| Shares Outstanding (Mil) | 65.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ascendis Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascendis Pharma AS Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-11 16:30 | In 143 days | ||
| Annual report for 2026 | 2027-02-11 | In 142 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-11 | In 142 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 52 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 51 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-15 08:30 | -- | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 08:00 | -- | ||
| Second quarter earnings results for 2026 | 2026-08-13 | -- | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | -- | ||
| First quarter earnings results for 2026 | 2026-05-07 | -- |
Show
Entries
Ascendis Pharma AS Frequently Asked Questions
What is Ascendis Pharma AS(MEX:ASND1N)'s stock price today?
The current price of MEX:ASND1N is MXN4424.97. The 52 week high of MEX:ASND1N is MXN4424.97 and 52 week low is MXN4270.00.
When is next earnings date of Ascendis Pharma AS(MEX:ASND1N)?
The next earnings date of Ascendis Pharma AS(MEX:ASND1N) is 2026-11-12 Est..
Does Ascendis Pharma AS(MEX:ASND1N) pay dividends? If so, how much?
Ascendis Pharma AS(MEX:ASND1N) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers